CTI opens new offices to support anticipated demand for regenerative medicine expertise

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Ankabala)
(Image: Getty/Ankabala)

Related tags: CTI Clinical Trial and Consulting Services, Regenerative medicine, Immune-oncology, Rare disease

The CRO is adding two new offices in the US to support what has been significant growth over the past several years from pharma and biotech customers working in rare diseases and immune-oncology.

CTI Clinical Trial and Consulting Services (CTI), contract research organization (CRO) headquartered in the Greater Cincinnati, OH area, with operations across North America, Europe, Latin America, and Asia-Pacific.

The company today announced the opening of new offices in Dallas, TX and San Diego, CA.

“We chose Dallas and San Diego because of the talent pool and other resources we see in those communities and the opportunities they present for both CTI and our pharmaceutical and biotechnology sponsors,”​ said Timothy Schroeder, CTI founder and CEO.

Schroeder said the specific job functions in the new offices will vary and include different clinical operations positions, with the services to be the same as the company’s other offices.

Several employees have already been hired at each office and more expected to be added in the coming months. “The rate of growth will be driven by the quality of the candidates,” ​explained Schroeder.

“In the past several years, we have seen significant growth from the pharmaceutical/biotechnology industry in the areas of cell and gene therapies, especially in rare diseases and immune-oncology,” ​he added.

Schroeder said, “As we’ve been working in the field since before it had a name, we anticipate demand for our regenerative medicine expertise to continue to increase.”

In line with this, the company in April​ doubled its footprint in Raleigh, NC and moved its West Coast office in San Francisco to a larger space. 

Related topics: Clinical Development, Phase I-II

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars